Recently, more and more clinical evidence has demonstrated that FGF21 is a prognosis biomarker for relevant cardiovascular diseases for its paradoxical upregulation expression during the onset stage of disease (33). This evidence concerns the gene FGF21 and cardiovascular disorder.